Clinical trial · Observational
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
NCT01960634CI-TRIAL-00017791BRAFV600completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples. Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard medical practice. The treatment is not the aim of the study. Patients can be treated either with specific or no-specific drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IV Skin Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Rate of patient in which BRAF V600 in blood samples is present/absent
- timeFrame
- two years
Secondary outcomes (1)
- measure
- Rate of patients with BRAFV600 present in tumor sample vs blood sample
- timeFrame
- two years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of melanoma and BRAFV600 * Signed Informed Consent Form * Unresectable phase III or phase IV melanoma * The patients should be starting a treatment for melanoma (either first line or subsequent lines)
References
Publications (0)
Data not yet available
No reference posted for this study.